Equities Analysts Offer Predictions for IDXX Q1 Earnings

IDEXX Laboratories, Inc. (NASDAQ:IDXX) – Equities research analysts at Leerink Partnrs lowered their Q1 2025 earnings per share (EPS) estimates for shares of IDEXX Laboratories in a report released on Monday, February 3rd. Leerink Partnrs analyst D. Clark now expects that the company will post earnings of $2.77 per share for the quarter, down from their prior forecast of $3.10. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for IDEXX Laboratories’ current full-year earnings is $10.45 per share. Leerink Partnrs also issued estimates for IDEXX Laboratories’ Q2 2025 earnings at $3.22 EPS, Q3 2025 earnings at $3.04 EPS, Q4 2025 earnings at $2.84 EPS, FY2025 earnings at $11.86 EPS, FY2026 earnings at $13.80 EPS, FY2027 earnings at $15.40 EPS and FY2028 earnings at $17.17 EPS.

A number of other equities research analysts have also recently commented on IDXX. Piper Sandler reiterated a “neutral” rating and set a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday. Bank of America lifted their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday. JPMorgan Chase & Co. decreased their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Finally, Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a report on Thursday, October 10th. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average price target of $524.38.

IDEXX Laboratories Trading Down 1.7 %

NASDAQ IDXX opened at $460.56 on Thursday. The stock has a market capitalization of $37.72 billion, a price-to-earnings ratio of 44.41, a PEG ratio of 3.64 and a beta of 1.37. IDEXX Laboratories has a one year low of $398.50 and a one year high of $583.39. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. The business’s fifty day moving average is $426.81 and its 200-day moving average is $453.62.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Raymond James Financial Inc. bought a new stake in IDEXX Laboratories in the 4th quarter worth approximately $71,893,000. Promus Capital LLC bought a new stake in IDEXX Laboratories in the 4th quarter worth approximately $604,000. Cullen Frost Bankers Inc. lifted its position in IDEXX Laboratories by 1.5% in the 4th quarter. Cullen Frost Bankers Inc. now owns 3,617 shares of the company’s stock worth $1,495,000 after buying an additional 52 shares during the last quarter. Proficio Capital Partners LLC bought a new stake in IDEXX Laboratories in the 4th quarter worth approximately $62,391,000. Finally, Assetmark Inc. lifted its position in IDEXX Laboratories by 83.4% in the 4th quarter. Assetmark Inc. now owns 33,804 shares of the company’s stock worth $13,976,000 after buying an additional 15,377 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the transaction, the director now owns 905 shares of the company’s stock, valued at $380,498.20. The trade was a 27.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 2.18% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.